**Supplementary Table S1 Secondary therapy for mHSPC patients who have progressed to mCRPC**

| Summary of secondary therapy, n (%) | AAP+ADT (n=11) | CAB (n=61) |
|------------------------------------|----------------|-------------|
| Flutamide                          | 0 (0)          | 25 (41.0)   |
| Enzalutamide                       | 7 (58.3)       | 8 (13.1)    |
| Abiraterone                        | 0 (0)          | 12 (19.7)   |
| Apalutamide                        | 0 (0)          | 1 (1.6)     |
| Docetaxel                          | 3 (25.0)       | 11 (18.0)   |
| Dexamethasone                      | 1 (8.3)        | 3 (4.9)     |
| Etinolestridol                     | 0 (0)          | 1 (1.6)     |

Abbreviations: mHSPC, metastatic hormone-sensitive prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; AAP, abiraterone acetate plus prednisone; ADT, androgen deprivation therapy; CAB, combined androgen blockade